Evidence map›Paper›PMID 36718449›Full record

ArticlePeerJ2023

Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells

Xinyue Wang, Songyi Qian, Siyi Wang, Sheng Jia, Nishang Zheng, Qing Yao, Jian Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xinyue Wang *Department of Nutrition, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
Songyi Qian *Department of Cardiac Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
Siyi WangDepartment of Nutrition, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
Sheng JiaDepartment of Nutrition, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
Nishang ZhengDepartment of Nutrition, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
Qing YaoDepartment of Nutrition, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian province, China.
Jian GaoDepartment of Nutrition, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNZhongshan Hospital of Xiamen University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenvatinib has become a first-line drug in the treatment of advanced hepatocellular carcinoma (HCC). Investigating its use in combination with other agents is of great significance to improve the sensitivity and durable response of Lenvatinib in advanced HCC patients. Vitamin C (L-ascorbic acid, ascorbate, VC) is an important natural antioxidant, which has been reported to show suppressive effects in cancer treatment. Here, we investigated the effect of the combination of VC and Lenvatinib in HCC cells

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsAscorbic AcidCell Line, TumorHumansPhenylurea CompoundsQuinolinesAntineoplastic AgentsAscorbic AcidlenvatinibPhenylurea CompoundsQuinolinesInvasionLenvatinibMigrationProliferationVitamin C

Identifiers

PMID36718449
PMCPMC9884045
OpenAlexW4317933096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.